SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-217452
Filing Date
2022-08-10
Accepted
2022-08-10 16:59:04
Documents
13
Period of Report
2022-08-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d301698d8k.htm   iXBRL 8-K 27008
2 EX-1.1 d301698dex11.htm EX-1.1 218554
  Complete submission text file 0001193125-22-217452.txt   434550

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tnya-20220810.xsd EX-101.SCH 2891
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20220810_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20220810_pre.xml EX-101.PRE 11731
7 EXTRACTED XBRL INSTANCE DOCUMENT d301698d8k_htm.xml XML 3490
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 221152524
SIC: 2836 Biological Products, (No Diagnostic Substances)